Enhancing transporter activity in heterologous expression systems with SAHA : a 2500‐times more potent and odorless alternative to butyrate
FEBS Open Bio · 2025
DOI: 10.1002/2211-5463.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Svenja Flögel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany. Hauptthemen laut MEDLINE: Vorinostat, Histone Deacetylase Inhibitors, Membrane Transport Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The functional characterization of plasma membrane transport proteins often relies on their heterologous expression in cultured cells. However, some transporters exhibit low activity, hindering meaningful functional assays. Heterologous expression is usually based on strong viral promoters which in living cells are prone to promoter silencing, a major problem. Here, we investigated the efficacy of low‐cost histone deacetylase (HDAC) inhibitors in enhancing transporter activity, comparing the established sodium butyrate (the sodium salt of butyric acid) with valproate/valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, also known as vorinostat). Using 293 cells stably transfected with pEBTet plasmids containing the CMV promotor to express the transporters SLC16A9, SLC22A15, and OATP1A2, we measured substrate efflux or uptake via LC–MS/MS following overnight preincubation with the HDAC inhibitors. All three compounds markedly stimulated transporter activity. VPA was less effective than butyrate but still surpassed control conditions. SAHA was cytotoxic at 6 μ m , but at 2 μ m , the enhancement was consistently comparable to 5 m m butyrate. Additionally, SAHA was more cost‐effective and devoid of the repulsive odor characteristic of butyrate. Our findings advocate for replacing butyrate with SAHA to enhance heterologously expressed transporter activity. This offers a more efficient and user‐friendly alternative for functional assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany.
ORCID-Profile: Dirk Gründemann
Zitieren
APA
Flögel, S., Tust, M., Boussettaoui, S., Fischer, D., & Gründemann, D. (2025). Enhancing transporter activity in heterologous expression systems with SAHA : a 2500‐times more potent and odorless alternative to butyrate. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70015
Vancouver
Flögel S, Tust M, Boussettaoui S, Fischer D, Gründemann D. Enhancing transporter activity in heterologous expression systems with SAHA : a 2500‐times more potent and odorless alternative to butyrate. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70015
BibTeX
@article{Flgel2025,
author = {Flögel, Svenja and Tust, Maurice and Boussettaoui, Samira and Fischer, Dietmar and Gründemann, Dirk},
title = {Enhancing transporter activity in heterologous expression systems with SAHA : a 2500‐times more potent and odorless alternative to butyrate},
journal = {FEBS Open Bio},
year = {2025},
doi = {10.1002/2211-5463.70015}
}
EUVIMED